GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Big Pharma Split Corp (TSX:PRM) » Definitions » EV-to-FCF

Big Pharma Split (TSX:PRM) EV-to-FCF : 1.36 (As of Jun. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Big Pharma Split EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Big Pharma Split's Enterprise Value is C$16.11 Mil. Big Pharma Split's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$11.86 Mil. Therefore, Big Pharma Split's EV-to-FCF for today is 1.36.

The historical rank and industry rank for Big Pharma Split's EV-to-FCF or its related term are showing as below:

TSX:PRM' s EV-to-FCF Range Over the Past 10 Years
Min: -2.21   Med: 1.83   Max: 20.26
Current: 1.36

During the past 7 years, the highest EV-to-FCF of Big Pharma Split was 20.26. The lowest was -2.21. And the median was 1.83.

TSX:PRM's EV-to-FCF is ranked better than
93.21% of 1045 companies
in the Asset Management industry
Industry Median: 13.38 vs TSX:PRM: 1.36

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Big Pharma Split's stock price is C$14.02. Big Pharma Split's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.530. Therefore, Big Pharma Split's PE Ratio for today is At Loss.


Big Pharma Split EV-to-FCF Historical Data

The historical data trend for Big Pharma Split's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Big Pharma Split EV-to-FCF Chart

Big Pharma Split Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial 1.65 2.83 -2.26 15.83 1.33

Big Pharma Split Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.26 - 15.83 - 1.33

Competitive Comparison of Big Pharma Split's EV-to-FCF

For the Asset Management subindustry, Big Pharma Split's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Big Pharma Split's EV-to-FCF Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, Big Pharma Split's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Big Pharma Split's EV-to-FCF falls into.



Big Pharma Split EV-to-FCF Calculation

Big Pharma Split's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=16.110/11.859
=1.36

Big Pharma Split's current Enterprise Value is C$16.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Big Pharma Split's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$11.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Big Pharma Split  (TSX:PRM) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Big Pharma Split's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.02/-0.530
=At Loss

Big Pharma Split's share price for today is C$14.02.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Big Pharma Split's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.530.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Big Pharma Split EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Big Pharma Split's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Big Pharma Split (TSX:PRM) Business Description

Traded in Other Exchanges
Address
610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a mutual fund corporation. Its investment objective is to provide shareholders with fixed cumulative preferential quarterly cash distributions, and regular monthly cash distributions. The company has a presence in the United States; Switzerland; France and United Kingdom.
Executives
Michael Kovacs Director, Senior Officer

Big Pharma Split (TSX:PRM) Headlines